The Monarch Etrial:improving the clinical outcome in HR^(+)/HER2^(−)early breast cancer:recent results and next steps

作     者：François Bertucci Pascal Finetti Emilie Mamessier Alexandre De Nonneville 

作者机构：Laboratory of Predictive OncologyCancer Research Center of MarseillePaoli-Calmettes InstituteAix-Marseille UniversityINSERM UMR1068CNRS UMR725Team Labelled“Ligue contre le cancer”MarseilleFrance Department of Medical OncologyPaoli-Calmettes InstituteMarseilleFrance 

出 版 物：《Cancer Communications》 (癌症通讯（英文）)

年 卷 期：2023年第43卷第8期

页      面：938-942页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Ligue Nationale Contre Le Cancer,Grant/Award Number:EL2022/FB Association Ruban Rose(Prix Ruban Rose 2020,FB) 

主　　题：HER2 cancer chemotherapy 

摘      要：Breast cancer(BC)is the most frequent cancer in women worldwide,and hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR^(+)/HER2^(−))is the most frequent BC *** adjuvant systemic treatment of HR^(+)/HER2^(−)early-stage BC(eBC),based on prognostic factors[1],sometimes includes chemotherapy,and in most cases,it includes endocrine therapy(ET).In the past decade,advancements in ET,such as successive approvals of tamoxifen and aromatase inhibitors and the extension of ET duration to 10 years in high-risk patients.